View Item 

Show simple item record

Changes in prostate‐specific antigen at the time of prostate cancer diagnosis after Medicaid expansion in young men
dc.contributor.authorWeiner, Adam B.
dc.contributor.authorVo, Amanda X.
dc.contributor.authorDesai, Anuj S.
dc.contributor.authorHu, Jim C.
dc.contributor.authorSpratt, Daniel E.
dc.contributor.authorSchaeffer, Edward M.
dc.date.accessioned2020-07-02T20:33:02Z
dc.date.availableWITHHELD_13_MONTHS
dc.date.available2020-07-02T20:33:02Z
dc.date.issued2020-07-15
dc.identifier.citationWeiner, Adam B.; Vo, Amanda X.; Desai, Anuj S.; Hu, Jim C.; Spratt, Daniel E.; Schaeffer, Edward M. (2020). "Changes in prostate‐specific antigen at the time of prostate cancer diagnosis after Medicaid expansion in young men." Cancer 126(14): 3229-3236.
dc.identifier.issn0008-543X
dc.identifier.issn1097-0142
dc.identifier.urihttps://hdl.handle.net/2027.42/155914
dc.publisherSpringer
dc.publisherWiley Periodicals, Inc.
dc.subject.otherUnited States
dc.subject.otherepidemiology
dc.subject.otherMedicaid
dc.subject.otherPatient Protection and Affordable Care Act
dc.subject.otherprostatic neoplasms
dc.subject.otheryoung adult
dc.titleChanges in prostate‐specific antigen at the time of prostate cancer diagnosis after Medicaid expansion in young men
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelPublic Health
dc.subject.hlbsecondlevelOncology and Hematology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/155914/1/cncr32930_am.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/155914/2/cncr32930.pdf
dc.identifier.doi10.1002/cncr.32930
dc.identifier.sourceCancer
dc.identifier.citedreferenceMoyer VA, US Preventive Services Task Force. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012; 157: 120 ‐ 134.
dc.identifier.citedreferenceHugosson J, Roobol MJ, Mansson M, et al. A 16‐year follow‐up of the European Randomized Study of Screening for Prostate Cancer. Eur Urol. 2019; 76: 43 ‐ 51.
dc.identifier.citedreferenceRoobol MJ, Grenabo A, Schroder FH, Hugosson J. Interval cancers in prostate cancer screening: comparing 2‐ and 4‐year screening intervals in the European Randomized Study of Screening for Prostate Cancer: Gothenburg and Rotterdam. J Natl Cancer Inst. 2007; 99: 1296 ‐ 1303.
dc.identifier.citedreferenceWinchester DP, Stewart AK, Bura C, Jones RS. The National Cancer Data Base: a clinical surveillance and quality improvement tool. J Surg Oncol. 2004; 85: 1 ‐ 3.
dc.identifier.citedreferenceSiegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016; 66: 7 ‐ 30.
dc.identifier.citedreferenceMohler JL, Antonarakis ES, Armstrong AJ, et al. Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019; 17: 479 ‐ 505.
dc.identifier.citedreferenceHan M, Partin AW, Zahurak M, Piantadosi S, Epstein JI, Walsh PC. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol. 2003; 169: 517 ‐ 523.
dc.identifier.citedreferenceFaisal FA, Sundi D, Pierorazio PM, et al. Outcomes of men with an elevated prostate‐specific antigen (PSA) level as their sole preoperative intermediate‐ or high‐risk feature. BJU Int. 2014; 114: E120 ‐ E129.
dc.identifier.citedreferenceEdge SB, Byrd DR, Compton CC, Fritz AG, Green FI, Trotti A, eds. AJCC Cancer Staging Manual. 7 th ed. Springer; 2010.
dc.identifier.citedreferenceDimick JB, Ryan AM. Methods for evaluating changes in health care policy: the difference‐in‐differences approach. JAMA. 2014; 312: 2401 ‐ 2402.
dc.identifier.citedreferenceDeSantis CE, Siegel RL, Sauer AG, et al. Cancer statistics for African Americans, 2016: progress and opportunities in reducing racial disparities. CA Cancer J Clin. 2016; 66: 290 ‐ 308.
dc.identifier.citedreferenceDeRouen MC, Schupp CW, Yang J, et al. Impact of individual and neighborhood factors on socioeconomic disparities in localized and advanced prostate cancer risk. Cancer Causes Control. 2018; 29: 951 ‐ 966.
dc.identifier.citedreferenceHoffman RM, Gilliland FD, Eley JW, et al. Racial and ethnic differences in advanced‐stage prostate cancer: the Prostate Cancer Outcomes Study. J Natl Cancer Inst. 2001; 93: 388 ‐ 395.
dc.identifier.citedreferenceMahal AR, Mahal BA, Nguyen PL, Yu JB. Prostate cancer outcomes for men aged younger than 65 years with Medicaid versus private insurance. Cancer. 2018; 124: 752 ‐ 759.
dc.identifier.citedreferenceMahal BA, Aizer AA, Ziehr DR, et al. The association between insurance status and prostate cancer outcomes: implications for the Affordable Care Act. Prostate Cancer Prostatic Dis. 2014; 17: 273 ‐ 279.
dc.identifier.citedreferenceSchroder FH, Hugosson J, Carlsson S, et al. Screening for prostate cancer decreases the risk of developing metastatic disease: findings from the European Randomized Study of Screening for Prostate Cancer (ERSPC). Eur Urol. 2012; 62: 745 ‐ 752.
dc.identifier.citedreferenceBuzzoni C, Auvinen A, Roobol MJ, et al. Metastatic prostate cancer incidence and prostate‐specific antigen testing: new insights from the European Randomized Study of Screening for Prostate Cancer. Eur Urol. 2015; 68: 885 ‐ 890.
dc.identifier.citedreferenceMokdad AH, Dwyer‐Lindgren L, Fitzmaurice C, et al. Trends and patterns of disparities in cancer mortality among US counties, 1980‐2014. JAMA. 2017; 317: 388 ‐ 406.
dc.identifier.citedreferenceDrazer MW, Huo D, Eggener SE. National prostate cancer screening rates after the 2012 US Preventive Services Task Force recommendation discouraging prostate‐specific antigen‐based screening. J Clin Oncol. 2015; 33: 2416 ‐ 2423.
dc.identifier.citedreferenceUS Preventive Services Task Force, Grossman DC, Curry SJ, et al. Screening for prostate cancer: US Preventive Services Task Force recommendation statement. JAMA. 2018; 319: 1901 ‐ 1913.
dc.identifier.citedreferenceWeiner AB, Matulewicz RS, Tosoian JJ, Feinglass JM, Schaeffer EM. The effect of socioeconomic status, race, and insurance type on newly diagnosed metastatic prostate cancer in the United States (2004‐2013). Urol Oncol. 2018; 36: 91.e91 ‐ 91.e96.
dc.identifier.citedreferenceRamirez E, Morano J, Beguiristain T, et al. Insurance status as a modifier of the association between race and stage of prostate cancer diagnosis in Florida during 1995 and 2013. Cancer Epidemiol. 2019; 59: 104 ‐ 108.
dc.identifier.citedreferenceGray PJ, Lin CC, Cooperberg MR, Jemal A, Efstathiou JA. Temporal trends and the impact of race, insurance, and socioeconomic status in the management of localized prostate cancer. Eur Urol. 2017; 71: 729 ‐ 737.
dc.identifier.citedreferenceDess RT, Hartman HE, Mahal BA, et al. Association of black race with prostate cancer‐specific and other‐cause mortality. JAMA Oncol. 2019; 5: 975 ‐ 983.
dc.identifier.citedreferenceBilimoria KY, Bentrem DJ, Stewart AK, Winchester DP, Ko CY. Comparison of Commission on Cancer‐approved and ‐nonapproved hospitals in the United States: implications for studies that use the National Cancer Data Base. J Clin Oncol. 2009; 27: 4177 ‐ 4181.
dc.identifier.citedreferenceSchroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate‐cancer mortality in a randomized European study. N Engl J Med. 2009; 360: 1320 ‐ 1328.
dc.identifier.citedreferencePucheril D, Zlatev DV, Mossanen M, et al. Impact of late Medicaid expansion on prostate cancer screening. J Clin Oncol. 2018; 36: 141 ‐ 141.
dc.identifier.citedreferenceMiller DC, Litwin MS, Bergman J, et al. Prostate cancer severity among low income, uninsured men. J Urol. 2009; 181: 579 ‐ 583; discussion 583‐574.
dc.identifier.citedreferenceFedewa SA, Etzioni R, Flanders WD, Jemal A, Ward EM. Association of insurance and race/ethnicity with disease severity among men diagnosed with prostate cancer, National Cancer Database 2004‐2006. Cancer Epidemiol Biomarkers Prev. 2010; 19: 2437 ‐ 2444.
dc.identifier.citedreferenceEllis L, Canchola AJ, Spiegel D, Ladabaum U, Haile R, Gomez SL. Trends in cancer survival by health insurance status in California from 1997 to 2014. JAMA Oncol. 2018; 4: 317 ‐ 323.
dc.identifier.citedreferenceMiller S, Wherry LR. Health and access to care during the first 2 years of the ACA Medicaid expansions. N Engl J Med. 2017; 376: 947 ‐ 956.
dc.identifier.citedreferenceHan X, Zhao J, Ruddy KJ, Lin CC, Sineshaw HM, Jemal A. The impact of dependent coverage expansion under the Affordable Care Act on time to breast cancer treatment among young women. PLoS One. 2018; 13: e0198771.
dc.identifier.citedreferenceJemal A, Lin CC, Davidoff AJ, Han X. Changes in insurance coverage and stage at diagnosis among nonelderly patients with cancer after the Affordable Care Act. J Clin Oncol. 2017; 35: 3906 ‐ 3915.
dc.identifier.citedreferenceFedewa SA, Yabroff KR, Smith RA, Goding Sauer A, Han X, Jemal A. Changes in breast and colorectal cancer screening after Medicaid expansion under the Affordable Care Act. Am J Prev Med. 2019; 57: 3 ‐ 12.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
cncr32930_am.pdf
Size:
336.2KB
Format:
PDF
View/Open
Name:
cncr32930.pdf
Size:
317.6KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.